Maurizio Comanducci, Georgina Tzanakaki, Laura Serino, Kumaran Vadivelu-Pechai, Philip S. Watson, Alessandro Muzzi, Julio A. Vázquez, Anna Skoczynska, Rino Rappuoli, Maija Toropainen, Alessandro Brozzi, Robert M. Mulhall, Ray Borrow, Maria Cecília Gorla, Muhamed-Kheir Taha, Raquel Abad, Dominique A. Caugant, Claudia Mikula, Gowrisankar Rajam, Michael D. Nissen, Pavla Křížová, Duccio Medini, Hanna Nohynek, Maria João Simões, Margherita Bodini, Paola Stefanelli, Ana Paula Silva de Lemos, GlaxoSmithKline Biologicals SA, GlaxoSmithKline [Siena, Italy] (GSK), Instituto de Salud Carlos III [Madrid] (ISC), Norwegian Institute of Public Health [Oslo] (NIPH), Instituto Adolfo Lutz [São Paulo, Brazil], National Institute of Public Health [Prague], Austrian Agency for Health and Food Safety (AGES), Irish Meningitis and Sepsis Reference Laboratory (IMSRL), Temple Street Children's University Hospital [Dublin], Queensland Paediatric Infectious Diseases Laboratory [Australia], University of Queensland [Brisbane]-Children's Health Research Centre, National Institute for Health and Welfare [Helsinki], Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), National Medicines Institute - Narodowy Instytut Leków [Warsaw] (NIL), Department of Infectious, Parasitic and Immune-Mediated Diseases [Rome], Istituto Superiore di Sanita [Rome], Centre National de Référence des Méningocoques et Haemophilus influenzae - National Reference Center Meningococci and Haemophilus influenzae (CNR), Institut Pasteur [Paris], National Meningitis Reference Laboratory, National School of Public Health Athens, GlaxoSmithKline [Rockville, USA] (GSK), Centers for Disease Control and Prevention [Atlanta] (CDC), Centers for Disease Control and Prevention, Meningococcal Reference Unit (MRU), Manchester Medical Microbiology Partnership [United Kingdom] (MMMP)-Public Health England [London], This work was supported by GlaxoSmithKline Biologicals SA, including all costs associated with the development and publishing of the manuscript., Istituto Superiore di Sanità (ISS), and Institut Pasteur [Paris] (IP)
Background: The Meningococcal Antigen Typing System (MATS) was developed to identify meningococcus group B strains with a high likelihood of being covered by the 4CMenB vaccine, but is limited by the requirement for viable isolates from culture-confirmed cases. We examined if antigen genotyping could complement MATS in predicting strain coverage by the 4CMenB vaccine. Methods: From a panel of 3912 MATS-typed invasive meningococcal disease isolates collected in England and Wales in 2007-2008, 2014-2015 and 2015-2016, and in 16 other countries in 2000-2015, 3481 isolates were also characterized by antigen genotyping. Individual associations between antigen genotypes and MATS coverage for each 4CMenB component were used to define a genetic MATS (gMATS). gMATS estimates were compared with England and Wales human complement serum bactericidal assay (hSBA) data and vaccine effectiveness (VE) data from England. Results: Overall, 81% of the strain panel had genetically predictable MATS coverage, with 92% accuracy and highly concordant results across national panels (Lin's accuracy coefficient, 0.98; root-mean-square deviation, 6%). England and Wales strain coverage estimates were 72-73% by genotyping (66-73% by MATS), underestimating hSBA values after four vaccine doses (88%) and VE after two doses (83%). The gMATS predicted strain coverage in other countries was 58-88%. Conclusions: gMATS can replace MATS in predicting 4CMenB strain coverage in four out of five cases, without requiring a cultivable isolate, and is open to further improvement. Both methods underestimated VE in England. Strain coverage predictions in other countries matched or exceeded England and Wales estimates. This work was supported by GlaxoSmithKline Biologicals SA,including all costs associated with the development and publishingof the manuscript. info:eu-repo/semantics/publishedVersion